期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 88, 期 2, 页码 188-191出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2017.03.006
关键词
Apramycin; Aminoglycoside; Activity spectrum; Acinetobacter; Pseudomonas aeruginosa; Repurposing
资金
- Chief Academic Officer's Pilot Grant from Beth Israel Deaconess Medical Center
- Long Term Health Education and Training Program from the US. Army Medical Department Center and School at Fort Sam Houston, TX
The in vitro activity of apramycin was compared to that of amikacin, gentamicin, and tobramycin against multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Apramycin demonstrated an MIC50/MIC90 of 8/32 mu g/ml for A. baumannii and 16/32 mu g/ml for P. aeruginosa. Only 2% of A. baumannii and P. aeruginosa had an MIC greater than an epidemiological cutoff value of 64 mu g/ml. In contrast, the MIC50/MIC90 for amikacin, gentamicin, and tobramycin were >= 64/>256 mu g/ml for A. baumannii with 57%, 95%, and 74% of isolates demonstrating resistance, respectively, and the MIC50/ MIC90 were >= 8/256 mu g/ml for P. aeruginosa with 27%, 50%, and 57% of strains demonstrating resistance, respectively. Apramycin appears to offer promising in vitro activity against highly resistant pathogens. It therefore may warrant further pre-clinical study to assess potential for repurposing as a human therapeutic and relevance as a scaffold for further medicinal chemistry exploration. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据